Fungtional Labs

Fungtional Labs: Integrated Supply Chain for Mushroom Cultivators in North America


Fungtional Labs is a leading provider of cultivation supplies and food-grade functional mushrooms in North America. The company’s vertically integrated business model provides robust differentiation over its peers. From cultivation and extraction to testing and end-product sales and distribution, the model ensures multiple revenue streams for Fungtional Labs.

Fungtional Labs’ cultivation supplies based on its proprietary all-in-one growing media include sterilized media, spawn genetics, all-in-one grow bags, pellets and masters mix. The company’s long-term goal is to develop IP around functional and psychedelic mushroom extracts.

Revenue Streams​Revenue Streams

Some of the company's revenue streams include selling food-grade gourmet and functional mushrooms in North America and bulk substrates, growing medias, genetics, growing equipment, which has generated significant demand among cultivators and commercial growers.

Company Highlights

  • Fungtional Labs is a vertically integrated business model that provides products from cultivation to end-product consumer sales and distribution. This provides an advantage over peers by eliminating intermediaries.
  • Fungtional Labs is a supplier of cultivation and genetic products for mushroom cultivators in North America, leveraging its proprietary all-in-one growing media. The company’s products include sterilized media, spawn genetics and all-in-one grow bags.
  • The company’s proprietary organic master mix growing media is in high demand among cultivators, providing higher yield at lower costs.
  • The company plans to implement its business model over three phases – Phase 1 will focus on providing mycological supplies and producing functional mushroom varieties; 2) Phase 2 will focus on processing finished products, as well as focus on submitting a licensed dealer application to manufacture psilocybin-enhanced products; and 3) Phase 3 will involve B2B white labelling services, as well as, operating as a licensed dealer in the psychedelics market.
  • The company’s mycological division, which supplies all-natural growth formulas and extraction methods, stands to benefit from sector tailwinds and a large addressable market. The global food fungi market is expected to grow to $69 billion by 2024, while the medicinal mushroom extract market is expected to reach $18 billion by 2024.
  • The company’s long-term goal is to develop IP around functional and psychedelic mushroom extracts. The company anticipates to provide different delivery systems to very evolving psychedelic market. The psychedelic market presents a large opportunity for the company given that the market is projected to grow at a CAGR of 16.3 percent by 2027.

This Fungtional Labs profile is part of a paid investor education campaign.*

Click here to connect with Fungtional Labs to receive an Investor Presentation

Lahontan Gold Corp.

Lahontan Gold Corp. Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

The Conversation (0)
Lahontan Gold Corp. (TSXV:LG)

Lahontan Gold Corp.

Near-term gold production pathway in the highly prolific Walker Lane district in Nevada

Near-term gold production pathway in the highly prolific Walker Lane district in Nevada Keep Reading...
Solvonis Therapeutics

Expansion of SVN-015 into Depression Following Positive Preclinical Data

Demonstrates antidepressant-like activity benchmarked against fluoxetine (Prozac®), supporting potential in patients with inadequate SSRI response

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces the expansion of its investigational compound SVN-015 into the treatment of depression, supported by preclinical data... Keep Reading...
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs for Investors in 2026

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies and the pharma market as a whole. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the... Keep Reading...
InMed Announces Results of 2025 Annual General and Special Meeting

InMed Announces Results of 2025 Annual General and Special Meeting

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general and special meeting of shareholders... Keep Reading...
InMed Provides Update on BayMedica Commercial Business

InMed Provides Update on BayMedica Commercial Business

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today released the following statement.Recently, H.R. 5371, the "Continuing... Keep Reading...
Thian Chew, CEO of Invion

Invion Advances Global Strategy With New Licencing Agreement

Invion (ASX:IVX) has taken a major step forward with a new global licencing agreement that streamlines its rights across key cancer and infectious disease programs. The move gives the company a clearer path to advance its Photosoft technology, expand market opportunities and strengthen... Keep Reading...
InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Data demonstrate a favorable bioavailability profile of INM-901 oral formulationData will support design and planning of first in human clinical trialsPreparing for pre-IND meeting with the FDA InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company... Keep Reading...
Lahontan Gold Corp.

Lahontan Gold Corp. Investor Kit

  • Corporate info
  • Insights
  • Growth strategies
  • Upcoming projects

GET YOUR FREE INVESTOR KIT

Interactive Chart

Latest Press Releases

Related News